Company Registration No. 13442273 (England and Wales)
Ran Pharmaceuticals Ltd
Unaudited accounts
for the year ended 30 June 2025
Ran Pharmaceuticals Ltd
Unaudited accounts
Contents
Ran Pharmaceuticals Ltd
Statement of financial position
as at 30 June 2025
Cash at bank and in hand
52,683
36,427
Creditors: amounts falling due within one year
(10,399)
(31,796)
Net current assets
52,619
26,086
Called up share capital
100
100
Profit and loss account
53,144
58,075
Shareholders' funds
53,244
58,175
For the year ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 12 September 2025 and were signed on its behalf by
Satpreet Singh Ran
Director
Company Registration No. 13442273
Ran Pharmaceuticals Ltd
Notes to the Accounts
for the year ended 30 June 2025
Ran Pharmaceuticals Ltd is a private company, limited by shares, registered in England and Wales, registration number 13442273. The registered office is 41 Olympic Way, Greenford, London, UB6 8NJ, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
Straight line over 3 years
4
Tangible fixed assets
Computer equipment
Ran Pharmaceuticals Ltd
Notes to the Accounts
for the year ended 30 June 2025
5
Investments
Other investments
Valuation at 1 July 2024
31,623
Valuation at 30 June 2025
-
Amounts falling due within one year
Trade debtors
10,335
21,455
7
Creditors: amounts falling due within one year
2025
2024
Taxes and social security
7,653
3,871
Loans from directors
346
25,525
8
Average number of employees
During the year the average number of employees was 1 (2024: 1).